Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Aten Primaria ; 54(10):102460, 2022.
Article in Spanish | PubMed | ID: covidwho-2035767

ABSTRACT

OBJECTIVE: To determine the association between post-traumatic stress disorder (PTSD) symptoms and health-related quality of life (HRQoL) of post-COVID-19 patients in primary care. DESIGN: Cross-sectional, multicenter, random probability sampling study. LOCATION: Primary care centers in Ica-Peru. PARTICIPANTS: Six hundred and thirty-six patients with previous diagnosis of COVID-19. MAIN MEASURES: The variable PTSD symptoms was measured with the COVID-19-PTSD questionnaire and HRQOL with the EuroQol scale (EQ-5D). Sociodemographic and health factors including post-COVID-19 syndrome were analyzed. A descriptive analysis was performed and crude and adjusted prevalence ratios (PR) were calculated using generalized linear models of the Poisson family to search for associations between variables. RESULTS: Of the participants, 21.4% presented symptoms of PTSD;33.6% symptoms of dysphoric and anxious arousal;22.3% intrusion, avoidance and negative affect;22.6% anhedonia;and 23.6% externalizing behavior. 50.3% revealed at least one component of HRQoL affected;35.5% problems linked to anxiety/depression;34.9% pain/discomfort;11% daily activity;10.7% mobility and 6.6% self-care. The presence of PTSD symptoms was associated with the HRQoL affected (PR=2.46: 95% CI: 2.19-2.78). Also, certain sociodemographic and health variables were associated with PTSD symptoms and affected HRQoL. CONCLUSIONS: PTSD symptoms, increase the probability of affecting the patient's HRQoL post COVID-19. There are potentially modifiable sociodemographic and health variables that could decrease PTSD symptoms and improve HRQoL.

2.
6th World Conference on Qualitative Research, WCQR 2022 ; 466 LNNS:65-81, 2022.
Article in English | Scopus | ID: covidwho-1872322

ABSTRACT

At a challenging juncture in the midst of the coronavirus pandemic (SARS-Cov-2- COVID-19), Global Health faces one of the greatest challenges in history to control the spread of the virus, whose main characteristic is the speed of contagion and high mortality rates. Risk communication is a fundamental component of any emergency response. Analyze the risk communication strategy developed by New Zealand in response to COVID-19. Qualitative research, based on the argumentation theory seeking to understand the production of symbolic phenomena, their social role, effects and meanings of the Risk Communication Strategy (RCS) developed in New Zealand. The collection consisted of 19 publications from the official website of the New Zealand government and 7 open access videos with statements made by the Prime Minister Jacinda Ardern, during the period from March to December 2020. The whole documentary corpus was analyzed using webQDA content analysis. In response to COVID-19 New Zealand developed a solid RCS, in which each of the components suggested by WHO were dynamically and creatively included, with a strong focus on community/diverse actor participation and promotion of solidarity as a core value of the New Zealand society, using clear and consistent messaging. The RCS gave relevance to decisions based on the best scientific evidence, with a marked promotion of non-pharmacological interventions. Qualitative research and CAQDAS such as webQDA are fundamental tools for studying relevant topics such as risk communication, emphasising political discourse and its implications in the development of strategies to control COVID-19 and the infodemic. A modern approach to argumentation theory and the pragmatic analysis of language allows both the assessment and critique of the forms of communication in health and offer elements for the search for answers to health crises, seeking to compensate for the asymmetry of knowledge and power. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.

3.
Revista Cubana de Educacion Medica Superior ; 35, 2021.
Article in Spanish | Scopus | ID: covidwho-1823748

ABSTRACT

Introduction: The COVID-19 pandemic can alter the moods and mental health of university students, making it difficult for them to achieve their goals and purposes. Objective: To describe the moods and mental health of students from a Peruvian university in the context of the COVID-19 pandemic. Methods: An observational, cross-sectional and descriptive study was carried out in a Peruvian university, during March and May 2020. With the participation of 302 university students, socio-educational data were collected and the Mood Assessment Scale was used, together with the 12-item General Health Questionnaire. The study variables were described and it was considered to evaluate differences. Results: 58.6% of the participants were female. Regarding their marital status, 76.8% were single, while 71.2% were Catholic. 48.3% presented an anxious mood;33.1%, hostile and 38.5%, depressed. In addition, 50.7% presented poor mental health;52.6%, general dysphoria and 74.8%, social dysfunction. Conclusions: In the context of the COVID-19 pandemic, there is a high prevalence of negative moods and mental health problems. These findings demonstrate the situation of social vulnerability, which influences the health and life projects of university students. It is necessary to promote group actions that contribute to the well-being of the student population. © 2021, Editorial Ciencias Medicas. All rights reserved.

4.
47th Latin American Computing Conference, CLEI 2021 ; 2021.
Article in Spanish | Scopus | ID: covidwho-1672589

ABSTRACT

Resumen—The COVID-19 pandemic has underlined that Emergency Department (ED) overcrowding is a critical factor in care services. Getting an approximation of the number of patients attending the department can assist in service resources planning and prevent overcrowding. In this manuscript we present the forecasting results for the admissions, inpatients and discharges series in ED by using different time aggregations (eight hours, twelve hours, one day and the service workers official shifts) and classical time series algorithms. Moreover, series forecasting is performed in two terms: long (four months ahead) and short (seven days ahead). The results show that time aggregations strongly influence the forecast quality, decreasing the effectiveness for one-day aggregations. In addition, best metrics are not obtained in the same aggregation, so there is no best aggregation for all cases. Therefore, it is essential to analyse the ED-related problem faced for the time aggregation selection. ©2021 IEEE

5.
Gastroenterology ; 160(6):S-160, 2021.
Article in English | EMBASE | ID: covidwho-1597728

ABSTRACT

Background/Aims: Digestive symptoms are common in patients with COVID-19. Neverthe-less, the evidence available so far is based on retrospective and observational studies. This prospective multicenter cohort study aimed to describe the frequency, intensity, evolution, and impact of digestive symptoms and complications, during hospitalization and after dis-charge, of patients with COVID-19. Methods: Patients hospitalized due to COVID-19 (posi-tive PCR for SARS-CoV-2) from May to August 2020, were prospectively recruited in 31 centers. Follow-up included the period between admission and 15 days after discharge. Results: 829 patients (mean age 56.7±17.9 years;42% of females) were enrolled in this study. Of these, 7.2% were active smokers and the mean BMI was 29.1±5.7. Proton pump inhibitors were used by 21.5% (n=178). The most prevalent symptoms on admission were diarrhea (39.4%), nausea (27.4%), and abdominal pain (20.7%). Anorexia, a non-specific symptom, was present in 49.8% of hospitalized patients. At discharge and 15 days after discharge, most symptoms resolved, returning to the baseline prevalence of patients (<5%). Digestive complications during admission were infrequent, except for liver injury defined as hypertransaminasemia which was present in 267 patients (32.3%). The mean length of hospital stay was 8 days (5-12) and 13.6% needed ICU admission. Death happened in 5.2%of patients. On multivariate analysis, diarrhea on admission was associated with a shorter hospital stay (<10 days) ORa 0.508 (0.350-0.739) p=0.000. During hospitalization, diarrhea, constipation, and abdominal bloating were associated with shorter hospital stay ORa 0.531 (0.298-0.946) p=0.032, ORa 0.384 (0.167-0.885) p=0.025, ORa 0.163 (0.057-0.466) p= 0.00, respectively.Odynophagia and dysphagia during hospitalization were associated with a higher need for ICU admission, ORa 6.518 (2.255-18.835) p=0.001 and ORa 4.035 (1.453-11.204) p=0.007, respectively. Liver injury during hospitalization was associated with a higher hospital stay (>10 days) ORa 1.442 (1.019-2.041) p=0.039. In the linear regression analysis, the set of GI symptoms and complications, along with age, comorbidity, and respiratory symptoms, were able to predict 43% (R2 0.43) of the observed variability in the speed of ICU admission;in this case, digestive symptoms slowed it down (more days until ICU admission). Conclusions: Gastrointestinal manifestations of COVID-19 are common in hospitalized patients, while complications are infrequent. Gastrointestinal symptoms seemed to predict a shorter hospital stay and slower speed of ICU admission. These tend to resolve to their baseline prevalence 15 days after discharge, while elevated transaminases were associated with a longer hospital stay. Odynophagia and dysphagia during hospitaliza-tion were associated with an increased need for ICU admission.

6.
Blood ; 138:2520, 2021.
Article in English | EMBASE | ID: covidwho-1582169

ABSTRACT

Updated analysis confirms sustained poor prognosis of COVID-19 in patients with lymphoma in Latin America: A cohort of 160 patients from GELL. Introduction: Ongoing SARS-COV-2 pandemic has impacted the management of cancer patients worldwide. Several reports have demonstrated inferior outcomes of patients with hematological malignancies, including higher rates of intensive care unit admission, need for mechanical ventilation and death. The impact of COVID-19 is profound in resource-restricted countries, including Latin America. Most cohorts reported have not included patients from Latin America, and there is paucity of data of the outcome of cancer patients with COVID-19 in low- and middle-income countries. Grupo de Estudio De Linfoproliferativos En Latino-America (GELL )is a collaborative network of hematological centers in 13 countries in Latin America. We report updated outcomes of lymphoma patients diagnosed with COVID-19 in Latin America. Methods: We conducted a retrospective study including patients with a diagnosis of lymphoma and COVID-19 infection. Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma were excluded from the analysis We defined active disease as follow: (1) patients with detectable disease either prior to initiating therapy or upon relapse, and/or (2) patients undergoing active cancer treatment. The primary outcome was overall survival at 100 days. Survival curves were estimated using the Kaplan Meier method. Uni and multivariable analysis were carried out with Cox model. Results: A total of 160 patients were available for analysis. Median age was 60 years old. Hypertension was the most common comorbidity (33%). Most patients had aggressive lymphomas (62%), including 43% of patients with diffuse large B-Cell lymphoma (DLBCL). Follicular lymphomas were observed in 13% of patients and Hodgkin lymphoma in 12.5% of patients. With a median follow-up of 37 days, the 100-day OS was 64% (95CI 56-74%, fig. 1). In univariate analysis, age (HR 1.03, p=0.0025), hypertension (HR 2.01, p=0.017), >1 number of prior lines (HR 2.78, p=0.011), patients currently on treatment (HR 1.83, p=0.043), ferritin >2000 ng/mL (HR 4.74 p=0.00047) were associated with inferior OS. In multivariate analysis, age (HR 1.03, p=0.0026) and patients currently on treatment (HR 1.82, p=0.04) had inferior OS. There was a trend towards inferior outcomes in patients receiving monoclonal antibodies in univariate analysis (HR 1.82, p=0.081) but not in multivariable analysis (HR=1.29, p=0.48). Use of steroids was not statistically related to mortality (HR 1.79, p=0.074). Finally, contrary to other cohorts, no improvement in OS was observed in patients diagnosed later on the pandemic (fig. 2). Conclusion: In this large cohort of Latin American patients with lymphoma malignancies, our updated analysis showed a maintained dismal prognosis with COVID-19 infection. With a median follow up of 37 days, the 100-day OS was 64%. Older age and ongoing active cancer treatment were significantly associated with mortality. The use of monoclonal antibodies and systemic corticosteroids were not statistically associated to poor survival. Current efforts are focused on improving immunization in the Latin American population. There is an unmet need for improving survival in patients with hematologic malignancies and COVID-19 infection. [Formula presented] Disclosures: Perini: Janssen: Honoraria, Speakers Bureau;Takeda: Honoraria, Speakers Bureau;Astra Zeneca: Honoraria, Speakers Bureau;MSD: Honoraria, Speakers Bureau. Otero: ASTRA ZENECA: Current Employment. Abello: Dr Reddy's: Research Funding;Amgen: Honoraria;Janssen: Honoraria. Castillo: Abbvie: Consultancy, Research Funding;BeiGene: Consultancy, Research Funding;Pharmacyclics: Consultancy, Research Funding;Janssen: Consultancy;Roche: Consultancy;TG Therapeutics: Research Funding.

7.
Drug Safety ; 44(12):1412, 2021.
Article in English | ProQuest Central | ID: covidwho-1543483

ABSTRACT

Background/Introduction: COVID-19 has had a significant impact in the last year. Research and implementation of new vaccines against SARS-Cov-2 have given hope of preventing its spread. They have not been tested in the entire population, hence the importance of events presumably attributable to vaccination and immunization (ESAVI's), the results will contribute to the biosafety of the vaccine, improve-ment in the effectiveness of pharmacovigilance of ESAVI's, implementation of measures to combat it. The institutional pharmacovigilance center was fundamental to carry out this study. Objective/Aim: Evaluation of events supposedly attributable to vaccination and immunization by Pfizer vaccine applied in front-line personnel of the National Institute of Cardiology (INC). Methods: Retrospective observational passive pharmacovigilance study of a cohort of first-line health personnel, all of whom worked in the care of patients with COVID-19 in a tertiary level hospital. The data obtained were captured in a database submitted for validation to the pharmacovigilance department and were analyzed. Results: The present study was conducted during the period December 2020 to March 2021, initial doses of Pfizer vaccine were administered to 1950 workers, reporting 59 events;1570 second doses, of which 63 ESAVI's were reported. Of the 127 reports obtained, 5 were discarded due to follow-up problems. The most frequent findings in relation to the total number of doses administered were headache (2.4%), pain/sensitivity at the site of application, asthenia and myalgia with 1.8% respectively, arthralgias (1.6%), fever and adynamia (1.4%). Conclusion: The Pfizer vaccine presented a very low incidence of ESAVI's in the first line personnel of the INC Ignacio Chavez. Symptoms appeared from 30 min to 4 h after application, 75% of the population that presented reaction in the first application, repeated in the subsequent application and it was observed that the persistence of symptoms was longer lasting. The most affected age group was 30-40 years old. Therefore, it is concluded that the analysis of ESAVI's in all vaccines is of great importance to evaluate the safety of each one of them.

8.
Multiple Sclerosis Journal ; 27(2 SUPPL):304-305, 2021.
Article in English | EMBASE | ID: covidwho-1495966

ABSTRACT

Introduction: Nowadays, Covid-19 pandemic seriously impact in general population mental status and quality of life. It is uncertain how these situation affect Multiple Sclerosis patients. Objectives: Analyze impact of Covid-19 pandemic in the quality of life in patients of a monographic Multiple Sclerosis Unit in a Spanish third level Hospital after one year Methods: Descriptive prospective study which analyzes changes in employment status, smoking habit, patient report outcomes (PROs) and Covid-19 incidence. Demographic variables (sex, age, employment status, smoking habit), and clinical (disease duration, EDSS, Covid-19 symptoms and PROs) were analyzed. Results: 100 patients Multiple Sclerosis. Median age 42.2 (SD 8.8). 74 % women. Disease duration: 11 years (1 - 37). EDSS 2 (0 - 7.5). 31 % was smoking in first evaluation. 83.3 % will not change after one year. In first assesment 47 % has an employment;1 % sick leave, 29 % inactive because disability;8 % pensioner, 9 % unemployement, 6 % another situation. In second evaluation 89.8 % does not change. 90.8 % have not Covid symptoms after one year and 3.1 % has infected SARS-Cov-2. 36 patients completed PROs in first evaluation and 25 in both. First MFIS median 34.8 (SD 17.13): physical 17.2 (SD 8.76), cognitive 15.75 (SD 9.25). Final MFIS median 38.4 (SD 17.38): physical 17.2 (SD 8.66), cognitive 17.56 (SD 10.3). Initial BDI 13.66 (SD 9.43);final BDI 11.21 (SD 9). Initial EuroQol 0.73 (SD 0.23);final 0.76 (SD 0.19). Conclusion: It does not seem that pandemic situation would have a negative impact about depression or anxiety in our patients. However, we observe a change in fatigue (physical and cognitive). It would be because of increase of sedentary life or the recently described “pandemic fatigue”.

10.
Educacion Medica ; 2021.
Article in English, Spanish | Scopus | ID: covidwho-1062319
SELECTION OF CITATIONS
SEARCH DETAIL